Chun S, Yun J W, Huh H J, Lee N Y
Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Kangnam-Gu, Seoul, 135-710, Korea.
Infection. 2015 Feb;43(1):59-64. doi: 10.1007/s15010-014-0696-z. Epub 2014 Nov 1.
Raoultella ornithinolytica is not well known as a clinical pathogen. We performed a retrospective review of R. ornithinolytica bacteremia to investigate its clinical features, antimicrobial susceptibility, and overall patient outcomes.
R. ornithinolytica bacteremia cases were collected from an electronic database of all cases of bacteremia over a 10-year period. Medical records were retrospectively reviewed. Demographic data, clinical information, the presence of underlying comorbidities, the results of antimicrobial susceptibility testing, and the antimicrobial regimen administered were investigated.
R. ornithinolytica was isolated from blood culture specimens in 16 cases. The majority of these patients had an underlying malignant condition of advanced stage (15 patients, 94 %). Seven of these patients had a solid tumor with lesions or metastases that extended to the bile duct or biliary tract. Neutropenic fever following hematologic stem cell transplantation was found in three cases. No resistance to piperacillin/tazobactam or imipenem was found. Four cases showed resistance to cefoxitin, while one of these cases showed resistance to multiple cephalosporins. In overall outcomes, seven patients (44 %) did not recover from the infection and subsequently expired.
R. ornithinolytica bacteremia occurs mainly in patients with underlying malignancies. The overall outcome was not favorable, despite favorable antimicrobial susceptibility test results. The findings of this study contradict those of other studies that demonstrated that infection from Raoultella species have good prognoses.
解鸟氨酸拉乌尔菌作为一种临床病原体并不广为人知。我们对解鸟氨酸拉乌尔菌血症进行了一项回顾性研究,以调查其临床特征、抗菌药物敏感性及患者总体预后情况。
从一个包含10年期间所有菌血症病例的电子数据库中收集解鸟氨酸拉乌尔菌血症病例。对病历进行回顾性分析。调查人口统计学数据、临床信息、基础合并症情况、抗菌药物敏感性试验结果以及所使用的抗菌治疗方案。
16例血培养标本中分离出了解鸟氨酸拉乌尔菌。这些患者大多数患有晚期恶性基础疾病(15例,94%)。其中7例患者患有实体瘤,其病变或转移灶累及胆管或胆道。3例患者出现血液系统干细胞移植后的中性粒细胞减少性发热。未发现对哌拉西林/他唑巴坦或亚胺培南耐药的情况。4例对头孢西丁耐药,其中1例对多种头孢菌素耐药。在总体预后方面,7例患者(44%)感染未愈,随后死亡。
解鸟氨酸拉乌尔菌血症主要发生在患有基础恶性肿瘤的患者中。尽管抗菌药物敏感性试验结果良好,但总体预后并不乐观。本研究结果与其他显示拉乌尔菌属感染预后良好的研究结果相矛盾。